Investigators assessed whether anti-tumor necrosis factor (TNF) agents increased the risk of developing psoriasis in patients with inflammatory bowel disease (IBD). In their meta-analysis, they found that anti-TNF therapy was not associated with greater frequency of psoriasis in this population. Findings were published in Medicine.
The systematic review identified 14 articles published to the PubMed, Embase, and Cochrane Library databases by April 2022. Subgroups included anti-TNF-treated and non-anti-TNF-treated patients, patients with ulcerative colitis and Crohn’s disease, and anti-TNF agent type.
Reportedly, no significant difference in risk of psoriasis development was observed between anti-TNF-treated and anti-TNF-naïve patients (relative risk [RR], 1.14; 95% CI, 0.77-1.68) or between anti-TNF-treated patients with ulcerative colitis and Crohn’s disease (RR, 1.30; 95% CI, 0.87-1.95). In addition, the researchers found no significant difference based on type of anti-TNF agent.
The study authors concluded that anti-TNF therapies could be considered for use in patients with IBD without an increased risk for developing psoriasis.
Reference: Jun YK, Park JY, Koh SJ, et al. Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis. Medicine (Baltimore). 2022;101(27):e29872. doi:10.1097/MD.0000000000029872
